title: Endozepine stupor: disease or deception? A critical review.
abstract: Presentation of patients with recurrent stupor associated with apparently elevated levels of an endogenous benzodiazepine-like agent, endozepine-4, has been reported from several centers, and a new syndrome, endozepine stupor has been proposed. We recently reported a case with typical features of this syndrome, which proved to be an example of surreptitious administration of exogenous benzodiazepine. This and other examples of clandestine drug use, together with uncertainties about the validity of tests used to distinguish exogenous and endogenous benzodiazepines, prompted us to undertake a reappraisal of this clinical syndrome.
authors.affiliation: Institute of Neurological Sciences, Prince of Wales Hospital, Australia. raduron@ozemail.com.au
authors.forename: Ron
authors.initials: R
authors.lastname: Granot
authors.forename: Samuel F
authors.initials: SF
authors.lastname: Berkovic
authors.forename: Scott
authors.initials: S
authors.lastname: Patterson
authors.forename: Malcolm
authors.initials: M
authors.lastname: Hopwood
authors.forename: Olaf H
authors.initials: OH
authors.lastname: Drummer
authors.forename: Rod
authors.initials: R
authors.lastname: Mackenzie
mesh_terms: D001569:Benzodiazepines / Q000008:administration & dosage / Q000009:adverse effects*; D003128:Coma / Q000097:blood* / Q000139:chemically induced*; D026261:Diazepam Binding Inhibitor / Q000378:metabolism*; D006801:Humans
chemical_list: D026261:Diazepam Binding Inhibitor; D001569:Benzodiazepines